MX349657B - Composiciones de vacuna de matriz de proteína que incluyen policationes. - Google Patents

Composiciones de vacuna de matriz de proteína que incluyen policationes.

Info

Publication number
MX349657B
MX349657B MX2013013358A MX2013013358A MX349657B MX 349657 B MX349657 B MX 349657B MX 2013013358 A MX2013013358 A MX 2013013358A MX 2013013358 A MX2013013358 A MX 2013013358A MX 349657 B MX349657 B MX 349657B
Authority
MX
Mexico
Prior art keywords
protein matrix
polycations
compositions including
vaccine compositions
matrix vaccine
Prior art date
Application number
MX2013013358A
Other languages
English (en)
Other versions
MX2013013358A (es
Inventor
P Killeen Kevin
T Cartee Robert
Original Assignee
Matrivax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrivax Inc filed Critical Matrivax Inc
Publication of MX2013013358A publication Critical patent/MX2013013358A/es
Publication of MX349657B publication Critical patent/MX349657B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a las composiciones inmunológicas que contienen uno o más antígenos de interés, una o más proteínas portadoras, y uno o más policationes, en donde el antígeno de interés se inmoviliza con la matriz de la proteína portadora entrecruzada y uno o más policaitones, método de fabricación de dichas vacunas y métodos de administración de la vacuna.
MX2013013358A 2011-05-18 2012-05-15 Composiciones de vacuna de matriz de proteína que incluyen policationes. MX349657B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487663P 2011-05-18 2011-05-18
PCT/US2012/037961 WO2012158701A1 (en) 2011-05-18 2012-05-15 Protein matrix vaccine compositions including polycations

Publications (2)

Publication Number Publication Date
MX2013013358A MX2013013358A (es) 2014-07-09
MX349657B true MX349657B (es) 2017-08-08

Family

ID=47177310

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013358A MX349657B (es) 2011-05-18 2012-05-15 Composiciones de vacuna de matriz de proteína que incluyen policationes.

Country Status (14)

Country Link
US (1) US9724401B2 (es)
EP (2) EP3524265A1 (es)
JP (1) JP6072777B2 (es)
KR (1) KR101670340B1 (es)
CN (1) CN103747798B (es)
AU (1) AU2012255878B2 (es)
BR (1) BR112013029417B1 (es)
CA (1) CA2836251C (es)
DK (1) DK2709656T3 (es)
ES (1) ES2728653T3 (es)
HK (1) HK1197033A1 (es)
MX (1) MX349657B (es)
WO (1) WO2012158701A1 (es)
ZA (1) ZA201309516B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012164480A1 (en) * 2011-05-30 2012-12-06 National Institute Of Immunology A vaccine composition capable of inducing memory antibody response from single point immunization
EP2946010B1 (en) 2013-01-18 2018-08-29 London School of Hygiene and Tropical Medicine Glycosylation method
GB201301085D0 (en) * 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
MX371453B (es) * 2014-01-21 2020-01-29 Pfizer Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
CN104548090B (zh) * 2015-01-27 2016-11-30 中国科学院过程工程研究所 一种β-葡聚糖修饰的脑膜炎多糖结合疫苗及其制备方法
SG11201901394XA (en) 2016-09-02 2019-03-28 Sanofi Pasteur Inc Neisseria meningitidis vaccine
JP2020536968A (ja) 2017-10-13 2020-12-17 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク 共生疾患進行に対する包括的ワクチン設計
EP3720483A2 (en) 2017-12-06 2020-10-14 Merck Sharp&Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CR20210333A (es) 2018-12-19 2021-08-18 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508108A (ja) 1991-03-28 1994-09-14 ニユコメド・イメージング・アクシエセルカペト 化学的化合物
CA2366908A1 (en) * 1999-03-24 2000-09-28 The Secretary Of State For Defence Vaccine composition
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
WO2005058940A2 (en) * 2003-12-17 2005-06-30 Wyeth Immunogenic peptide carrier conjugates and methods of producing same
ZA200900899B (en) * 2006-08-07 2010-07-28 Harvard College Protein matrix vaccines and methods of making and administering such vaccines
TWI565713B (zh) 2006-08-07 2017-01-11 哈佛大學校長及研究員協會 蛋白基質疫苗以及該疫苗的製造與使用方法
US20090142362A1 (en) 2006-11-06 2009-06-04 Avant Immunotherapeutics, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
CA2692021A1 (en) 2007-06-28 2008-12-31 Capsutech Ltd Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
US20120231086A1 (en) * 2009-09-09 2012-09-13 Killen Kevin P Protein matrix vaccines of improved immunogenicity
WO2011036560A2 (en) 2009-09-23 2011-03-31 Novartis Ag Glycoconjugate compositions and methods for treatment of hiv

Also Published As

Publication number Publication date
HK1197033A1 (en) 2015-01-02
US9724401B2 (en) 2017-08-08
JP2014513726A (ja) 2014-06-05
CA2836251A1 (en) 2012-11-22
KR20140045416A (ko) 2014-04-16
ZA201309516B (en) 2017-04-26
EP2709656A4 (en) 2015-01-14
EP3524265A1 (en) 2019-08-14
AU2012255878B2 (en) 2016-05-12
EP2709656B1 (en) 2019-03-27
KR101670340B1 (ko) 2016-10-28
DK2709656T3 (da) 2019-06-24
EP2709656A1 (en) 2014-03-26
ES2728653T3 (es) 2019-10-28
AU2012255878A1 (en) 2013-05-02
CA2836251C (en) 2017-07-04
BR112013029417B1 (pt) 2022-10-25
US20140086989A1 (en) 2014-03-27
BR112013029417A2 (pt) 2017-01-31
JP6072777B2 (ja) 2017-02-01
CN103747798B (zh) 2018-10-26
WO2012158701A1 (en) 2012-11-22
CN103747798A (zh) 2014-04-23
MX2013013358A (es) 2014-07-09

Similar Documents

Publication Publication Date Title
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
AU2017279565B2 (en) RNA formulation for immunotherapy
EP4056198A3 (en) Outer membrane vesicles
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EA201391240A1 (ru) Слитые белки и комбинированные вакцины, содержащие белок е и пилин а haemophilus influenza
MX352974B (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
WO2010104749A8 (en) Antigen presenting cell targeted cancer vaccines
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
EA201891124A2 (ru) Новые мукозные адъюванты и системы доставки
EA201790239A1 (ru) Молекула-носитель для антигенов
EA201491171A1 (ru) Вещества, содержащие улучшенные генетические конструкции il-12, вакцины, иммунотерапевтические составы и способы их применения
MX2014009845A (es) Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos.
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
NZ603863A (en) Concentration and lyophilization of influenza vaccine antigens
MX2013012219A (es) Método de administración de vacunas.
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
CY1123453T1 (el) Σκευασμα rna για ανοσοθεραπεια
EA201291437A1 (ru) Концентрация вакцинных антигенов без лиофилизации
MX2014001626A (es) Preservacion asistida con vacio de productos biologicos, en particular de vacunas.
AU2014232363A8 (en) Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
MX2016014868A (es) Metodos para secar por congelacion y rehidratar productos biologicos.
MX2013013228A (es) Particulas similares a virus y proceso para prepararlas.
MX2019007924A (es) Vacunas contra la influenza.

Legal Events

Date Code Title Description
FG Grant or registration